Authors | Study design | Subjects | Results/outcomes |
---|---|---|---|
Rho et al. (2010) [19] | Cross-sectional study evaluating correlation between HOMA-IR and serum adipokine levels. | 169 RA patients | No correlation between visfatin levels and IR |
Alkady et al. (2011) [52] | Case-control study evaluating correlation between serum and synovial liquid adipokines and disease activity. | 70 RA patients 30 controls | Positive correlation between serum visfatin levels and disease activity. |
Khalifa et al. (2013) [53] | Case-control study evaluating correlation between serum visfatin and inflammation markers. | 60 RA patients 20 controls | Positive correlation between visfatin levels and IL-6, CRP, ERS, TNF-α and DAS-28 in RA. |
El-Hini et al. (2013) [54] | Case-control study evaluating metabolic disorder and its association with clinical characteristics of RA patients. | 40 RA patients 40 controls | Positive correlations between serum visfatin levels and IR, cholesterol, triglycerides and LDL-C. |
Meyer et al. (2013) [56] | Cohort study evaluating serum adipokine levels and radiographic progression of RA. | 632 RA patients at early stage of disease and 159 with unspecific arthritis | No correlation between visfatin levels and progression of RA. |
Sglunda et al. (2014) [55] | Prospective study evaluating visfatin level and its relationship with disease activity and serum lipids. | 40 patients with early, treatment-naïve RA 30 controls | Correlation between visfatin levels and disease activity and reduced levels after treatment. |
Mirfeizi et al. (2014) [30] | Cross-sectional study evaluating correlation between serum adipokines levels and radiographic joint damage. | 54 RA patients (29 with erosion and 25 without erosion) | The levels of visfatin were higher in patients with radiographic joint damage and dependent on the duration of the disease. |